Critical congenital heart disease (CCHD) screening is a point-of-care check that uses pulse oximetry to look for serious heart defects in the first days of life. It is not a blood-spot or genetic test. Instead, it measures the oxygen level in a newborn’s blood, because several of the most dangerous heart defects cause oxygen levels to drop before any other sign appears. Critical CHDs affect roughly 2 in 1,000 newborns, and early detection can be lifesaving.
What CCHD screening detects
The screen targets a group of critical heart defects that typically require intervention in the first weeks of life, including conditions such as hypoplastic left heart syndrome, transposition of the great arteries, tetralogy of Fallot, and truncus arteriosus. Catching these before a baby becomes critically ill allows for prompt cardiology evaluation and treatment.
How the pulse oximetry screen works
A soft sensor is placed on the baby’s right hand and on one foot, usually after 24 hours of age, to compare oxygen saturation in both locations. The test is painless, takes only a few minutes, and involves no needles. A healthy result shows normal oxygen levels with little difference between the two sites.
What a positive screen means
A positive (or "fail") result does not by itself diagnose a heart defect. Low oxygen can have other causes, such as infection or normal transition after birth. The standard next step is an echocardiogram, an ultrasound of the heart, along with evaluation by a pediatrician or pediatric cardiologist to determine the cause.
The genetic side of heart defects
Many congenital heart defects have a genetic component. Some occur as part of genetic syndromes, such as 22q11.2 deletion syndrome or Down syndrome, while others are linked to variants in specific heart-development genes. Because pulse oximetry measures oxygen rather than genes, it cannot identify an underlying genetic cause on its own.
How genetic screening fits in
State newborn screening does an excellent job of catching critical heart defects. Genetic screening looks at the same picture from the DNA level and, in a single test, can also assess the genes tied to more than 1,000 other clinically actionable childhood conditions, many of which are not on any state panel. Fore Genomics offers an at-home cheek-swab screen, sequenced in CLIA-certified and CAP-accredited labs, with results supported by board-certified genetic counselors. See how your state’s panel compares, see what we screen for, or start screening.
Frequently asked questions
Is CCHD screening required in every state?
Pulse oximetry screening for CCHD is standard newborn practice across U.S. states, typically performed after 24 hours of age.
Does the CCHD screen involve a needle?
No. It uses a soft external sensor on the hand and foot and is completely painless.
What if my baby fails the CCHD screen?
A failed screen means further evaluation is needed, usually an echocardiogram. Many babies who fail do not have a heart defect, but prompt follow-up is important.
Medically reviewed by Fore’s Clinical Team. This article is for general educational purposes and is not medical advice. Sources: American Academy of Pediatrics; HRSA Newborn Screening.